Shows
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 2For years, disease diagnosis and treatment have focused on a few biomarkers, overlooking thousands of vital biological signals. Despite biotech advances, most therapies are still based on limited data, missing countless breakthroughs.Multiomics changes that. By analyzing tens of thousands of proteins, metabolites, and lipids, it reveals hidden insights, paving the way for smarter, faster, and more effective medical discoveries.In this must-listen episode, David Brühlmann welcomes Mo Jain, founder and CSO of Sapient, a pioneering force in bringing multiomic platforms out of academia and into the heart of drug development. A physician-scientist by t...2025-07-1022 min
Deep DiveCathie WoodCathie Wood, a prominent investor overseeing nearly $30 billion, who shares her insights on the future of investing. Wood highlights Artificial Intelligence (AI) as the most significant technological disruption in history, predicting massive investment and job opportunities for those on the "right side of change." She champions Tesla as the largest AI project on Earth, forecasting its stock to reach $2,600 in five years, primarily due to its robotaxi platform and future humanoid robots. Additionally, Wood discusses the potential of Bitcoin as a new asset class, projecting its value to reach $1.5 million by 2030, driven by institutional adoption and its role as...2025-06-2315 min
This Week In Medicine5 26 2025Hi, This Week in Medicine, we will be discussingNew England Journal of MedicineOveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1 Second-Line Antiretroviral Therapy for Children Living with HIV in Africa Journal of American Medical AssociationDexmedetomidine- or Clonidine-Based Sedation Compared With Propofol in Critically Ill Patients: The A2B Randomized Clinical Trial A Multidimensional Diagnostic Approach for Chronic Obstructive Pulmonary Disease Annals of Internal MedicineCo...2025-05-2621 min
Dr RR Baliga's "Got Knowledge Doc" Podkast🔬 Antioxidants & Health: The Science Behind the Hype ❌❤️🔬 Antioxidants & Health: Myths vs. Reality ❌🍊💊 Despite popular belief, vitamins C & E do not reduce the risk of cancer, heart disease, or chronic illness 🚫❤️. High doses of vitamin A increase the risk of hip fractures & prostate cancer ⚠️🦴, while vitamin E is linked to respiratory infections, prostate cancer, and even death 😷❌. However, a specific combination of antioxidants (C, E, zinc, copper, lutein, zeaxanthin) slows vision loss in age-related macular degeneration (AMD) 👁️🧡. A multiomic study identified GSTO1 as the best biomarker for zinc deficiency 🧪🔍, but further validation is needed. Takeaway? Antioxidants have specific benefits...2025-03-1502 min
Shape of TomorrowEpisode 124 - Greetings from LatisanaWhile traveling through the timeless towns of Latisana, Udine, San Daniele, and Venzone, I found myself reflecting on the paradox of permanence in a world shaped by exponential technologies. This episode explores that tension and dives deep into ARK Invest’s Big Ideas 2025 report, unpacking how converging innovation platforms—AI, Robotics, Energy Storage, Blockchain, and Multiomic Sequencing—are set to reshape industries and societies. Join me as I consider what this future means not just for global economies, but for the quiet places where time seems to stand still.2025-03-1417 min
The Geonomics PodcastElement founders Molly He and Michael PreviteEarly this week I got to sit with Element Biosciences founders Molly He (CEO) and Michael Previte (CTO) in their comically big board room and we had a great in-depth conversation about their careers and building Element.All up a fantastic discussion and in my humble 😏 opinion an entire MBA packed into one hour of easy listening!1. How the hell did you two get here?- Molly’s personality: competitive sprinting, love of travel and risk-taking, proteomics obsession- Mike’s early work in cancer research, multi-drug resista...2025-03-1350 min
Curiosophy: A Future Forward Cast.Analysis of ARK "Big Ideas 2025" reportARK Invest's "Big Ideas 2025" report presents key areas of disruptive innovation driving future economic growth, emphasizing the convergence of five technology platforms: Artificial Intelligence, Robotics, Energy Storage, Public Blockchains, and Multiomic Sequencing. The report highlights investment opportunities and potential transformations across various sectors, evaluating each "big idea" based on technological advancements, market potential, and expected growth trajectories. These platforms are examined individually, with particular emphasis on their interconnectedness and catalytic effects on one another. The document also discusses risks associated with investing in innovation, such as regulatory hurdles and competitive pressures, and serves as a forward-looking guide for investors.2025-02-0727 min
Infectious Disease PuscastInfectious Disease PuscastOn episode #73 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 1/16/25 – 1/29/25. Hosts: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation (Gastroenterology) Host-microbe multiomic profiling identifies distinct COVID-19 immune dysregulation in solid organ transplant recipients (Nature Communications) Insect-specific RNA viruses detection in Field-Caught Aedes aegypti mosquitoes from Argentina using NGS technology (PLoS Neglected Tropical Diseases) Bacterial Oral regimens for rifampin-resistant, fluoroquinolone-s...2025-02-0433 min
The Cogitating Ceviché PodcastThe Illumina-NVIDIA Partnership:Discussion provided by NotebookLMThe recent partnership between Illumina, a leader in genetic sequencing, and NVIDIA, a pioneer in artificial intelligence (AI) and accelerated computing, marks a significant milestone in genomics and drug discovery. This collaboration promises to redefine how genomic data is analyzed and applied in clinical and pharmaceutical settings, potentially transforming the healthcare industry.The Strategic CollaborationIllumina’s Core StrengthsIllumina has long been at the forefront of genomic sequencing, providing technologies that enable the rapid and accurate reading of DNA. Notable achievements include the development of high-throughput se...2025-01-2110 min
Redefining MedicineRedefining Medicine with special guest John Catanzaro, PhDDr. John Catanzaro serves as CEO, Founder, Chairman, and Product Development Officer of Neo7Bioscience, a precision/personalized molecular design biotech company. Dr. Catanzaro received his Doctorate of Naturopathic Medicine (NMD) from Bastyr University in 1995 and his Doctorate of Theology in Science and Medical Ethics (Ph.D. and Th.D.) from Bethany Divinity Seminary in 2012. After 22 years of clinical practice treating patients with cancer and chronic illness, he retired in 2017, where he was the founder and CEO of a cancer institute and research development group of genetic and proteomic technology innovating patient-precision genetically matched immunopeptides. In addition, Dr. Catanzaro...2024-12-3118 min
FYI - For Your InnovationRedefining Medicine: Nobel Laureate David Baker On AI In Drug DiscoveryIn this episode of FYI, ARK Chief Investment Strategist Dr. Charles Roberts and ARK Analyst Nemo Despot, PhD speak with David Baker, Nobel Prize-winning scientist and pioneer in protein engineering. Baker shares insights into his revolutionary work on Rosetta and the evolution of AI-driven protein design tools. With advances in technologies like RoseTTAFold and generative AI, he discusses how the field is moving towards designing proteins that can neutralize pathogens, catalyze chemical reactions, and potentially combat neurodegenerative diseases. Charlie and Nemo also examine the implications for healthcare, aging, and drug discovery as Baker envisions a future where synthetic biology...2024-11-1450 min
Translating ProteomicsPlasma Proteomics - The Dream and the NightmareDo you have a question you'd like answered on a future episode of Translating Proteomics? Send it to translatingproteomics@nautilus.bio!On this episode of Translating Proteomics, hosts Parag Mallick and Andreas Huhmer of Nautilus Biotechnology discuss the challenges and opportunities of plasma proteomics. Their conversation focuses on:· Why blood plasma may be a good source of protein biomarkers· Current methodologies and pitfalls in plasma proteomics· The path forward for plasma proteomicsWhat is Plasma Proteomics?For those who are new to this topic, plasma is the liquid portion of the b...2024-10-2829 min
Podcastul Raportuldegardă.roAu fost identificate 4 noi tipuri de Boală Alzheimer | Dr. Marius Geantă | #știința360În cadrul ediției de pe 22 octombrie 2024 a emisiunii Știința360 de pe Radio România Cultural, Dr. Marius Geantă, Președintele Centrului pentru Inovație în Medicină, a comentat ultimele noutăți din domeniul sănătății.
Cercetătorii de la Beth Israel Deaconess Medical Center au identificat patru profiluri moleculare distincte ale bolii Alzheimer (AD) folosind o abordare cross-omics.
Studiul, publicat în PLOS BIOLOGY, a relevat că unul dintre aceste profiluri este asociat cu o funcție cognitivă mai slabă și caracteristici neuropatologice mai severe. Utilizând tehnici de învățare automată pentru a integra date transc...2024-10-2425 min
JCO Precision Oncology ConversationsMolecular Characteristics of Early-Onset Biliary Tract CancerJCO PO author Dr. Alok A. Khorana, MD, FASCO, Professor of Medicine, Cleveland Clinic and Case Comprehensive Cancer Center, shares insights into the JCO PO article, “Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers.” Host Dr. Rafeh Naqash and Dr. Khorana discuss how multiomic analysis shows higher FGFR2 fusions and immunotherapy marker variations in early-onset biliary cancer. TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO POarticles. I'm your host, Dr. Rafeh Naqash...2024-09-1825 min
DeviceTalks Podcast NetworkHologic's FDA-cleared Genius Digital Dx Systems leads AI innovation in cervical cancer preventionIn this episode of DeviceTalks AI, we explore the advancements in AI-driven technologies in women's health and cancer diagnostics.
In our keynote interview, we speak with Michael Quick, Vice President of R&D and Innovation in Cytology & Oncology at Hologic. Quick shares his journey from a pre-med student to a leader in cytology innovation. He discusses the development and impact of Hologic’s Genius Digital Diagnostic Systems, the first FDA-approved digital cytology system, which leverages AI to enhance cervical cancer screening accuracy and efficiency. Michael emphasizes Hologic’s dedication to women's health and the critical role of AI in addressing the...2024-07-0957 minDeviceTalks Podcast NetworkHologic's FDA-cleared Genius Digital Dx Systems leads AI innovation in cervical cancer preventionIn this episode of DeviceTalks AI, we explore the advancements in AI-driven technologies in women's health and cancer diagnostics.
In our keynote interview, we speak with Michael Quick, Vice President of R&D and Innovation in Cytology & Oncology at Hologic. Quick shares his journey from a pre-med student to a leader in cytology innovation. He discusses the development and impact of Hologic’s Genius Digital Diagnostic Systems, the first FDA-approved digital cytology system, which leverages AI to enhance cervical cancer screening accuracy and efficiency. Michael emphasizes Hologic’s dedication to women's health and the critical role of AI in addressing the...2024-07-0957 min
The Scientist SpeaksUnderstanding the Effects of Extrachromosomal DNA on CancerIn the 1960s, researchers in England noticed an anomaly when investigating chromosomes from surgically removed human tumors. Distinct from the intact chromosomes visible underneath the microscope were numerous “very small double chromatin bodies,” which are today better known as extrachromosomal DNA. Thanks to modern sequencing and imaging techniques, researchers now know that these tiny bits of circular DNA play a big role in cancer outcomes.
In this episode, Niki Spahich from The Scientist spoke with Lukas Chavez, an assistant professor in the Cancer Genome and Epigenetics Program at the Sanford Burnham Prebys Medical Discovery Institute, to learn more...2024-05-2921 min
BioChat, a Podcast by ABclonal TechnologyBioChat #23: Genetic and Multiomic Analysis On Your BenchtopBioChat invites Sam Bettis, Associate Director for Field Applications for Element Biosciences, to speak to us about his broad expertise through his winding career path, the impact and innovation possible through next-generation sequencing, and the advantages and benefits of the Element platform in facilitating rapid discovery.
Element Biosciences delivers high-quality, affordable benchtop sequencing to help innovate genetic and multiomic analysis for the research market. You can learn about their state-of-the-art sequencing platforms at ElementBiosciences.com!
Please feel free to visit us at www.abclonal.com and read our blog posts here, includin...2024-05-1530 min
Translating ProteomicsSingle-protein Biomarkers Don't Cut ItDo you have a question you'd like answered on a future episode of Translating Proteomics? Send it to translatingproteomics@nautilus.bio!Protein biomarkers are proteins measured as indicators of biological processes. People often hope biomarkers will take the form of elevated or decreased amounts of single proteins, but few single protein measurements provide specific and sensitive indications of biological processes. In this episode of Translating Proteomics, Parag and Andreas discuss why it is difficult to find new biomarkers and describe how new techniques can enable the development of multi-protein, multi-time point, and even multiomic biomarkers that have...2024-05-0821 minTranslating ProteomicsBiology in Space and TimeDo you have a question you'd like answered on a future episode of Translating Proteomics? Send it to translatingproteomics@nautilus.bio!It's no surprise that biological systems change dramatically over space and time, but we often ignore these dynamics when comparing biological samples. In the latest episode of Translating Proteomics, Parag and Andreas discuss why it's essential to take space and time into account and envision ways we can design experiments that explicitly incorporate spacial and temporal considerations.Chapters:00:00 - Biological systems as dynamic, adaptive systems04:45 - How current experimental designs...2024-04-2421 min
AI and HealthcareFighting Cancer Smarter: The Power of DataDr. Sanjay Juneja interviews David Hysong and Katherine Arline from Shepherd, a precision oncology platform. They discuss the limitations of traditional cancer treatment guidelines and the need for a more personalized approach. Shepherd uses multiomic data, including RNA sequencing, to assess a patient's unique tumor characteristics and recommend tailored therapies. They also consider collateral medications and potential side effects.2024-04-1953 min
FYI - For Your InnovationGeorge Church: Decoding the Future of GenomicsOn this episode of FYI, ARK Multiomics analyst Nemo Marjanovic sits down with Professor George Church, a renowned geneticist and entrepreneur from Harvard. They discuss the evolution of genomic sequencing technologies, the intersection of genomics and blockchain for privacy, and the fascinating potential of DNA for data storage. They delve into multiomic approaches for enhanced biological understanding, the transformative impact of artificial intelligence (AI) in medical advancements, and George's groundbreaking research on aging. Key Points From This Episode:Evolution of genomic sequencing: from short to long readsBalancing privacy with blockchain in genomicsThe potential o...2024-04-1130 min
PRACTICING with Dr. Nathan GoodyearSPACE MEDICINE: The Future of Integrative Wellness with John CatanzaroThe annals of history will eternally remember those who ventured boldly into the unknown, bridging the frontiers of the cosmos with human wellness. The darkest hour is indeed just before the dawn, and only a few stand at the forefront of discovery.
Join Dr. Goodyear and CEO of Neo7Bioscience, John Catanzaro, on this fascinating episode of the PRACTICING with Dr. Nathan Goodyear podcast, where individuals will have the opportunity to broaden their horizons and have a glimpse into the future of medicine, at the intersection of space and holistic health.
This is a conversation you really won't want to miss...2023-10-1056 minPRACTICING with Dr. Nathan GoodyearSPACE MEDICINE: The Future of Integrative Wellness with John CatanzaroThe annals of history will eternally remember those who ventured boldly into the unknown, bridging the frontiers of the cosmos with human wellness. The darkest hour is indeed just before the dawn, and only a few stand at the forefront of discovery.
Join Dr. Goodyear and CEO of Neo7Bioscience, John Catanzaro, on this fascinating episode of the PRACTICING with Dr. Nathan Goodyear podcast, where individuals will have the opportunity to broaden their horizons and have a glimpse into the future of medicine, at the intersection of space and holistic health.
This is a conversation you really won't want to miss...2023-10-1056 min
Casual SpaceAdriana Blachowicz is Guarding the GalaxyAdriana Blachowicz may just have one of the MOST IMPORTANT JOBS on our planet… and perhaps one of the coolest! Adriana is a planetary protection scientist at NASA’s Jet Propulsion Laboratory where she works to prevent microbial transfer between the Earth and other planets. So how can we protect as we explore? Why should we care about planetary protection? What are extremophiles? Can microbes live in an inhospitable environment? Does finding water really equate to finding life? In this episode, Adriana helps answer these questions, and shares some amazing insights on how she serves as a guard for our gal...2023-10-0254 min
The BioInsights PodcastApplying multiomics to novel target discovery in immuno-oncologyIn this episode, Róisin McGuigan, Editor, Immuno-Oncology Insights, speaks with Eran Ophir, Chief Scientific Officer, Compugen, and Yaron Turpaz, Senior Vice President and Senior Advisor, Data and Informatics Solutions, Compugen, about the advantages of using multiomic and computational approaches for the discovery of novel targets and mechanisms of action (MoA) of novel drug candidates in immuno-oncology.2023-08-0818 min
Progress, Potential, and Possibilities Podcast / ShowDr. Angeli Möller, Ph.D - Head, Data and Integrations Generating Insights Group (DIGI), Roche - Bringing Together Data & Technology To Enable Innovation For PatientsSend us a textDr. Angeli Möller, Ph.D, is Head of the Data and Integrations Generating Insights Group (DIGI) at Roche ( https://www.roche.com/ ), which is a fascinating group focused on bringing together data & technology from Roche diagnostics and pharma divisions to enable innovation for patients. Previously, Dr. Möller served as Head of Pharma Informatics International at Roche focused specifically on driving the employment of AI technologies to help get the right treatment to the right patient at the right time. Prior to joining Roche, Dr. Möller led the artificial intelligence workstream and...2023-06-281h 00
FYI - For Your InnovationBig Ideas Monday Mini: Precision Therapies
Welcome to the Big Ideas Monday Miniseries, brought to you by the For Your Innovation Podcast.
Big Ideas is meant to enlighten investors on the long-term impact of innovation. This annual research report seeks to highlight the technological breakthroughs evolving today and creating the potential for super-exponential growth tomorrow.
We believe that innovation is taking off now, corroborating our original research and boosting our confidence that ARK’s strategies are on the right side of change.
To learn more, view Big Ideas 2023.
This week’s Big Ideas Monday Mini Episode focuses on P...2023-06-1228 min
Gladden Longevity Podcast -- formerly Living Beyond 120A Major Tool in Cracking the Code of Aging & Youthfulness Do you know that personalized solutions are more precise and targeted and offer direct mediation? Do you need insights about dealing with cancer? Join Dr. Jeffrey Gladden, Steve Reiter and John Catanzaro in this episode of the Gladden Longevity Podcast. John Catanzaro is the CEO, Founder, and Product Development Officer of Neo7Bioscience, a precision/personalized molecular design biotech company. He retired from clinical practice in 2017, where he was the Founder and CEO of a cancer institute and research development of genetic and proteomic technology innovating patient-precision genetically matched immunopeptides. He is the co-inventor of a precision augmentation platform kn...2023-03-0257 min
The UpFlip Podcast60. How to Run and Scale Multiple Businesses (The Right Way)Most entrepreneurs would consider running one million-dollar company enough of a challenge, but not Serge Faguet. He runs five, from the video communication platform Telefonica to the AI medicine development company Multiomic Health. He shares his insights and advice on scaling a business empire in this interview. Balancing multiple businesses is a challenge at any size, and especially so when they’re large, multinational companies. You’ll find out what systems and tools Serge uses to keep all of his businesses running smoothly, even when life gets in the way. Building a strong team, and trusting in their...2023-02-2730 min
CWL Conference 2023Decomprolute: a benchmarking platform designed for multiomic tumor deconvolutionPresenter: Sara Gosline, PhD (Pacific Northwest National Laboratory)
Summary: Tumor deconvolution is a reliable way to disentangle the diverse cell types that comprise solid tumors. To date, however, both the algorithms developed to deconvolve tumor samples, and the gold standard datasets used to assess the algorithms are geared toward the analysis of gene expression (e.g., RNA-seq) rather than protein levels in tumor cells. While gene expression is less expensive to measure, protein levels provide a more accurate view of immune markers. To facilitate the development as well as improve the reproducibility and reusability of multi-omic deconvolution...2023-02-2500 min
CWL Conference 2023Decomprolute: a benchmarking platform designed for multiomic tumor deconvolutionPresenter: Sara Gosline, PhD (Pacific Northwest National Laboratory)
Summary: Tumor deconvolution is a reliable way to disentangle the diverse cell types that comprise solid tumors. To date, however, both the algorithms developed to deconvolve tumor samples, and the gold standard datasets used to assess the algorithms are geared toward the analysis of gene expression (e.g., RNA-seq) rather than protein levels in tumor cells. While gene expression is less expensive to measure, protein levels provide a more accurate view of immune markers. To facilitate the development as well as improve the reproducibility and reusability of multi-omic deconvolution...2023-02-2500 minPRACTICING with Dr. Nathan GoodyearPEPTIDES: An Interview with Neo7Bioscience CEO - Dr. John CatanzaroIn this week's episode, Dr. Goodyear interviews Dr. John Catanzaro, owner and CEO of Neo7Bioscience about the incredible science behind peptides and their use in a variety of treatments, including cancer.
ABOUT DR. JOHN CATANZARO
Dr. John Catanzaro serves as CEO, Founder, Chairman, and Product Development Officer of Neo7Bioscience, a precision/personalized molecular design biotech company.
Dr. Catanzaro received his Doctorate of Naturopathic Medicine (N.M.D.) from Bastyr University in 1995, and his Doctorate of Theology and Ethics (D.T.S; Th.D.) from Bethany Divinity Seminary in 2012.
2023-02-1648 minPRACTICING with Dr. Nathan GoodyearPEPTIDES: An Interview with Neo7Bioscience CEO - Dr. John CatanzaroIn this week's episode, Dr. Goodyear interviews Dr. John Catanzaro, owner and CEO of Neo7Bioscience about the incredible science behind peptides and their use in a variety of treatments, including cancer.
ABOUT DR. JOHN CATANZARO
Dr. John Catanzaro serves as CEO, Founder, Chairman, and Product Development Officer of Neo7Bioscience, a precision/personalized molecular design biotech company.
Dr. Catanzaro received his Doctorate of Naturopathic Medicine (N.M.D.) from Bastyr University in 1995, and his Doctorate of Theology and Ethics (D.T.S; Th.D.) from Bethany Divinity Seminary in 2012.
2023-02-1648 min
MoonlyСергей Фаге: инновации, изобилие, людиСергей Фаге — выпускник Stanford и Cornell University, серийный tech-предприниматель, основатель стартапов в области биотехнологий и искусственного интеллекта. В их числе Ostrovok.ru, Tokbox, Multiomic Health, Novami, Nexus, Mirror AI, Identix.Сергей — глубоко убеждённый трансгуманист, верит, что предпринимательские идеи должны служить для достижения комфортного и устойчивого будущего. Он считает, что ключ к решению глобальных проблем человека XXI века лежит в децентрализации финансовой и политической организации мира за счет перехода к Web3.В этом подкасте он поделился историей своего становления и рассказал, как ему удается генерировать большое количество идей и реализовывать их в рамках одновременного развития 8 компаний в сфере биотехнологий и долголетия.Узнать больше о проектах и связаться с Сергеем: www.sergefaguet.com/ www.t.me/Faguet www.twitter.com/SergeW1 Сергей Фаге в Instagram: www.instagram.com/sergefaguet/Moonly в Instagram: www.instagram.com/moonlyappСкачать приложение Moonly: www.moonly.appЗадать вопрос и обсудить сотрудничество: hi@moonly.app2023-01-1316 min
The Jim Rutt ShowCurrents 077: Serge Faguet on Consciousness and Post-AGI EthicsJim continues his conversation with Serge Faguet, this time focusing on the nature of consciousness and its implications for the wise and ethical use of AI systems...Jim continues his conversation with Serge Faguet, this time focusing on the nature of consciousness and its implications for the wise and ethical use of AI systems. They discuss a technological Singularity, the evolution & significance of consciousness, integrated information theory (IIT) vs. John Searle's arguments, whether current AIs exhibit consciousness, applying the golden rule to AIs, AI alignment, consciousness as solution to the combinatoric explosion of inference, the importance of systems thinking, an...2022-12-301h 26The Jim Rutt ShowCurrents 074: Serge Faguet on Building MetacommunityJim talks with Serge Faguet about emerging transnational networks of cooperation...Jim talks with Serge Faguet about emerging transnational networks of cooperation. They discuss the mismatch between rates of technological development & cooperation abilities, building a good Singularity, uniting an already-existing movement, "the right way to live" as a root of evil, coherent pluralism as a basis for metacommunity, taking responsibility for the world, a coming fork in humanity's future, bringing the universe to life, examples of decentralized community-building, opportunities for applying large language models, technological tools for communities, psychological issues & the insanity of society, TikTok as pure monetization without virtue...2022-11-2957 min
DnextDnext: SERGE FAGUET from MOSCOWSerge Faguet is a serial tech entrepreneur and a prominent thinker in the Web3 space. To date he has personally raised more than $100m of capital, and has co-founded numerous breakthrough tech companies:
- Emerging Travel Group, a multi-billion-dollar B2B online travel company;
- Novami, a concierge medicine delivery company;
- Multiomic Health, an AI drug discovery company;
- Nexus, an company specializing in automated clinical trial recruitment;
- Identix, a product designed to ease the onboarding process from Web2 to Web3.
As an advocate for...2022-11-1533 min
Proteomics in ProximityProteomic Profiling PlatformsThe 2022 Science Advances paper, “Proteomic profiling platforms head to head: Leveraging genetics and clinical traits to compare aptamer- and antibody-based methods” by Daniel H Katz and Rob Gerszten et al. is available online here.A highly informative Twitter thread by the first author Dr. Daniel Katz reviewing the figures of the paper is available here.If you are interested in learning more about the use of proteomics in multiomic strategies, here’s link to the Olink website where examples of combinations of omics methods are combined.If you would like to contact Dale, Cindy...2022-10-2532 min
Utility + FunctionSerge Faguet: Who are we, what have we accomplished, and where are we going?Serge Faguet is a Russian-Ukrainian entrepreneur and thinker. He has founded multiple tech companies including multi-billion-dollar B2B online travel company Emerging Travel Group, concierge medicine care delivery company Novami, AI drug discovery company Multiomic Health, automated clinical trial recruitment company Nexus and Web2 ⇒ Web3 onboarding product Identix.
A proponent of biohacking, his vision is to build a large-scale commercial data/biobank that gathers healthcare data to make major progress in increasing productivity, longevity, and quality of life. As a philosopher-entrepreneur, Serge believes that we need to adopt a syncretic approach to innovation; he uses entrepreneurial ideation to...2022-10-131h 43
The Pharma Letter PodcastCan AI find new drugs for metabolic diseases?Interest in the potential for artificial intelligence to transform different aspects of the drug discovery and development process is at an all-time high.According to industry analyst GlobalData, the number of AI deals in pharma has doubled in the last three years, reaching 85 in 2021, and more pharmaceutical companies are hiring for AI roles than ever before.Another way of gauging interest is to look at the number of AI-based patents granted over time, with analysts recording a three-fold increase since 2015.While the broad picture is clear, a detailed look at where this activity...2022-07-0141 min
Epigenetics PodcastSingle-Cell Technologies using Microfluidics (Ben Hindson, CSO of 10x Genomics)In this episode of the Epigenetics Podcast, we caught up with Ben Hindson, Chief Scientific Officer at 10X Genomics, to talk about single-cell technologies using microfluidics.
Epigenetics has moved well past a simple understanding of a single epigenetic layer of control at genomic regions of interest, thanks to advances in many techniques and the application of “multiomics”. We can now analyze genome-wide histone modification patterns, transcription factor binding profiles, chromatin accessibility profiles, three-dimensional chromosomal conformation, and DNA methylation dynamics combined with transcriptomic analyses and associated analytical platforms.
Bulk Assays, like ATAC-Seq or ChIP, despite all thei...2022-03-1638 min
Talking TechniquesRevealing the regulome: using multiomic approaches to explore epigenetics and DNA expressionExplore the realm of epigenetics and gene expression, discovering the different omic ‘lenses’ used to examine these processes and the power of single-cell studies to reveal a comprehensive multiomic view of cells and their biology. This episode features the ever-buoyant Will Greenleaf, Associate Professor of Genetics at Stanford University School of Medicine (CA, USA) and head of the Greenleaf Lab. Will takes us through his lab’s work, detailing his attempts to understand the compacting of DNA into cell nuclei and how this impacts gene expression and epigenetic regulation.Discover the emerging new research...2021-06-1133 min
Future Science GroupRevealing the regulome: using multiomic approaches to explore epigenetics and DNA expressionExplore the realm of epigenetics and gene expression, discovering the different omic ‘lenses’ used to examine these processes and the power of single-cell studies to reveal provide a comprehensive multiomic view of cells and their biology.
This episode features the ever-buoyant Will Greenleaf, Associate Professor of Genetics at Stanford University School of Medicine (CA, USA) and head of the Greenleaf Lab. Will takes us through his lab’s work, detailing his attempts to understand the compacting of DNA into cell nuclei and how this impacts gene expression and epigenetic regulation.
Discover the emerging new research focus that Will has coined the “Reg...2021-06-1133 min